Cell entry of dengue virus

Future Virology

Volumn 3, Issue 5, 2008, Pages 471-479

  Acosta, Eliana G ^a   Talarico, Laura B ^a   Damonte, Elsa B ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Antiviral therapy; Dengue virus; Envelope E glycoprotein; Flavivirus; Receptor; Virus attachment; Virus entry

Indexed keywords

AMANTADINE; CD14 ANTIGEN; CHLORPROMAZINE; CONCANAVALIN A; GALACTAN; GLUCAN; GLUCOSE REGULATED PROTEIN 78; GLYCOPROTEIN E1; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEPARIN; LAMININ RECEPTOR; LECTIN; MANNOSE RECEPTOR; PENTOSAN POLYSULFATE; PI 88; POLYANION; RIMANTADINE; SURAMIN; SYNTHETIC PEPTIDE; TETRACYCLINE DERIVATIVE; TUBULIN; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; DENGUE; DENGUE VIRUS; HOST RANGE; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS REPLICATION;

AEDES AEGYPTI; DENGUE VIRUS; FLAVIVIRUS; MAMMALIA;

EID: 55849152458     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.5.471     Document Type: Review

References (71)

1. Gubler DJ: Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11, 480-496 (1998).
2. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS: Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40, 444-451 (1989).
3. Rothman AL: Dengue: defining protective versus pathologic immunity. J. Clin. Inv. 113, 946-951 (2004).
4. Gubler DJ: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10, 100-103 (2002).
5. Salas-Benito JS, del Angel RM: Identification of two surface proteins from C6/36 cells that bind dengue type 4 virus. J. Virol. 71, 7246-7252 (1997).
6. Salas-Benito J. Reyes-Del Valle J, Salas-Benito M, Ceballos-Olvera I, Mosso C, del Angel RM: Evidence that the 45-kD glycoprotein, part of a putative dengue virus receptor complex in the mosquito cell line C6/36, is a heat-shock related protein. Am. J. Trop. Med. Hyg. 77, 283-290 (2007).
7. Muñoz ML, Cisneros A, Cruz J, Das P, Tovar R, Ortega A: Putative dengue virus receptors from mosquito cells. FEMS Microbiol. Lett. 168, 251-258 (1998).
8. Chee H-Y, AbuBakar S: Identification of a 48 kDa tubulin or tubulin-like C6/36 mosquito cells protein that binds dengue virus 2 using mass spectrometry. Biochem. Biophys. Res. Commun. 320, 11-17 (2004).
9. Sakoonwatanyoo P, Boonsanay V, Smith DR: Growth and production of the dengue virus in C6/36 cells and identification of a laminin-binding protein as a candidate serotype 3 and 4 receptor protein. Inter Virology 49, 161-172 (2006).
10. Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM: Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol. 79, 4557-4567 (2005).
11. Jindadamrongwech S, Thepparit C, Smith DR: Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch. Virol. 149, 915-927 (2004).
12. Thepparit C, Smith DR: Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J. Virol, 78, 12647-12656 (2004).
13. Miller JL, Dewet BJ, Martinez-Pomares L et al.: The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4, e17 (2008).
14. Chen Y, Maguire T, Marks RM: Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70, 8765-8772 (1996).
15. Chen YC, Wang SY, King CC: Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a cD14-dependent mechanism. J. Virol. 73, 2650-2657 (1999).
16. Navarro-Sanchez E, Altmeyer R, Amara A et al.: Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4, 723-728 (2003).
17. Tassaneetrithep B, Burgess TH, Granelli-Piperno A et al.: DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197, 823-829 (2003).
18. Marianneau P, Mégret F, Olivier R, Morens DM, Deubel V: Dengue 1 virus binding to human hepatoma HepG2 and simian Vero cell surfaces differs. J. Gen. Virol. 77, 2547-2554 (1996).
19. Rothwell SW, Putnak R, La Russa VF: Dengue-2 virus infection of human bone marrow: characterization of dengue-2 antigen-positive stromal cells. Am. J. Trop. Med. Hyg. 54, 503-510 (1996).
20. Ramos-Castañeda J, Imbert JL, Barron BL, Ramos C: A 65-kDa trypsin sensible membrane cell protein as a posible receptor for dengue virus in cultured neuroblastoma cells. J Neurovirol. 3, 435-440 (1997).
21. Bielefeldt-Ohmann H: Analysis of antibody-independent binding of dengue viruses and dengue virus envelope protein to human myelomonocytic cells and B lymphocytes. Virus Res. 57, 63-79 (1998).
22. Bielefeldt-Ohmann H, Meyer M, Fitzpatrick DR, Mackenzie JS: Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. Virus Res. 73, 81-89 (2001).
23. Martínez-Barragán JJ, del Angel RM: Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection. J. Virol. 75, 7818-7827 (2001).
24. Moreno-Altamirano MMB, Sánchez-García FJ, Mu-tinoz ML: Non Fc receptor-mediated infection of human macrophages by dengue virus serotype 2. J. Gen. Virol. 83, 1123-1130 (2002).
25. Wei HY, Jiang LF, Fang DY, Guo HY: Dengue virus type 2 infects human endothelial cells through binding of the viral envelope glycoprotein to cell surface polypeptides. J. Gen. Virol. 84, 3095-3098 (2003).
26. Chen Y, Maguire T, Hileman RE et al.: Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3, 866-871 (1997).
27. Hung SL, Lee PL, Chen HW Chen LK. Kao CL, King CC: Analysis of the steps involved in dengue virus entry into host cells. Virology 257, 156-167 (1999).
28. Hilgard P, Stockert R: Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32, 1069-1077 (2000).
29. Germi R, Crance JM, Garin D et al.: Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 292, 162-168 (2002).
30. Spillmann D: Heparan sulfate: anchor for viral intruders. Biochimie 83, 811-817 (2001).
31. Lin YL, Lei HY, Lin YS, Yeh TM, Chen SH, Liu HS: Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Res. 56, 93-96 (2002).
32. Talarico LB, Pujol CA, Zibetti RGM et al.: The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 66, 103-110 (2005).
33. Lozach PY, Burleigh L, Staropoli I et al.: Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J. Biol. Chem. 280, 23698-23708 (2005).
34. Pelkmans L: Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses. Biochim. Biophys. Acta 1749, 295-304 (2005).
35. Kirkham M, Parton RG: Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim. Biophys. Acta 1745, 273-286 (2005).
36. Sieczkarski SB, Whittaker GR: Influenza virus can enter and infect cells in the absence of clathrin-mediated endocytosis. J. Virol. 76, 10455-10464 (2005).
37. Marsh M, Helenius A: Virus entry: open sesame. Cell 124, 729-740 (2006).
38. Hase T, Summers PL, Eckels KH: Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes. Arch. Virol. 104, 129-143 (1989).
39. Lim HY, Ng ML: A different mode of entry by dengue-2 neutralization escape mutant virus. Arch. Virol. 144, 989-995 (1999).
40. Krishnan MN, Sukumaran B, Pal U et al. Rab 5 is required for the cellular entry of dengue virus and West Nile viruses. J. Virol. 81, 4881-4885 (2007).
41. Acosta EG, Castilla V, Damonte EB: Functional entry of dengue virus into Aedes albopictus mosquito cells is dependent on clathrin-mediated endocytosis. J. Gen. Virol. 89, 474-484 (2008).
42. Hu H-P, Hsieh SC, King C-C, Wang W-K: Characterization of retrovirus-based reporter viruses pseudotyped with the precursor membrane and envelope glycoproteins of four serotypes of dengue viruses. Virology 368, 376-387 (2007).
43. Randolph VB, Stollar V: Law pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures. J. Gen. Virol. 71. 1845-1850 (1990).
44. van der Schaar HM, Rust MJ, Waarts B-L et al.: Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J. Virol. 81, 12019-12028 (2007).
45. Modis Y, Ogata S, Clements D, Harrison SC: Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319 (2004).
46. Zhang Y, Zhang W, Ogata S et al.: Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618 (2004).
47. Mukhopadhyay S, Kuhn RJ, Rossmann MG: A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13-22 (2005).
48. Stiasny K, Heinz FX: Flavivirus membrane fusion. J. Gen. Virol. 87, 2755-2766 (2006).
49. Lee C-J, Lin H-R, Liao C-L, Lin Y-L: Cholesterol effectively blocks entry of flavivirus infection. J. Virol. 82, 6470-6480 (2008).
50. Altmeyer R: Virus attachment and entry offer numerous targets for antiviral therapy. Curr. Pharm. Des. 10, 3701-3712 (2004).
51. Thaisomboonsuk BK, Clayson ET, Pantuwatana S, Vaughn DW, Endy TP: Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells. Am. J. Trop. Med. Hyg. 72, 375-383 (2005).
52. Marks RM, Lu H, Sundaresan R et al.: Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J. Med. Chem. 44, 2178-2187 (2001).
53. Lee E, Pavy M, Young N, Freeman C, Lobigs M: Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 69, 31-38 (2006).
54. Pujol CA, Estévez JM, Carlucci MJ, Ciancia M, Cerezo AS, Damonte EB: Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir. Chem. Chemother. 13, 83-89 (2002).
55. Talarico LB, Duarte MER, Zibetti RGM, Noseda MD, Damonte EB: An algal derived DL-galactan hybrid is an efficient preventing agent for in vitro dengue virus infection. Planta Med. 73, 1464-1468 (2007).
56. Qiu H, Tang W, Tong X, Ding K, Zuo J: Structure elucidation and sulfated derivatives preparation of two α-D-glucans from Gastrodia elata B1 and their anti-dengue virus bioactivities. Carbohydr. Res. 342, 2230-2236 (2007).
57. Rodríguez MC, Merino ER, Pujol CA, Damonte EB, Cerezo AS, Matulewicz MC: Galactans from cystocarpic plants of the red seaweed Callophyllic variegata (Kallymeniaceae, Gigartinales). Carbohydr. Res. 340, 2742-2751 (2005).
58. Tischer PCSF, Talarico LB, Noseda MD, Guimarees SMPB, Damonte EB, Duarte MER: Chemical structure and antiviral activity of carrageenans from Meristiella gelidium against herpes simplex and dengue virus. Carbohydr. Polym. 63, 459-465 (2006).
59. Talarico LB, Damonte EB: Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363, 473-485 (2007).
60. Ono L, Wollinger W, Rocco IM, Coimbra TLM, Gorin PAJ, Sierakowski MR: In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antiviral Res. 60, 201-208 (2003).
61. Shigeta S, Mori S, Kodama E, Kodama J, Takahashi K, Yamase T: Broad-spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Res. 58, 265-271 (2003).
62. Damonte EB, Pujol CA, Coto CE: Prospects for the therapy and prevention of dengue virus infections. Adv. Virus Res. 63, 239-285 (2004).
63. Koff WC, Elm JL Jr, Halstead SB: Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob. Agents Chemother. 18, 125-129 (1980).
64. Koff WC, Elm JL Jr, Halstead SB: Suppression of dengue virus replication in vitro by rimantadine hydrochloride. Am. J. Trop. Med. Hyg. 30, 184-189 (1981).
65. Nawa M, Takasaki T, Yamada K, Kurane I, Akatsuka T: Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine. J. Gen. Virol. 84, 1737-1741 (2003).
66. Kuhn RJ, Zhang W, Rossmann MG et al.: Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725 (2002).
67. Modis Y, Ogata S, Clements D, Harrison SC: A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl Acad. Sci. USA 100, 6986-6991 (2003).
68. Modis Y, Ogata S, Clements D, Harrison SC: Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79. 1223-1231 (2005).
69. Volk DE, Lee Y-C, Li X et al.: Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364, 147-154 (2007).
70. Hrobowski YM, Garry RF, Michael SF: Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol. J. 2, 49 (2005).
71. Yang J-M, Chen Y-F, Tu Y-Y, Yen K-R. Yang Y-L: Combinatorial computational approaches to identity tetracycline derivatives as flavivirus inhibitors. PLoS One 2, e428 (2007).